125 related articles for article (PubMed ID: 31077356)
21. Preclinical Evaluation of Gastrin-Releasing Peptide Receptor Antagonists Labeled with
Holzleitner N; Cwojdzinski T; Beck R; Urtz-Urban N; Hillhouse CC; Grundler PV; van der Meulen NP; Talip Z; Ramaekers S; Van de Voorde M; Ponsard B; Casini A; Günther T
J Nucl Med; 2024 Mar; 65(3):481-484. PubMed ID: 38124121
[TBL] [Abstract][Full Text] [Related]
22. Head-to-head comparison of three chelates reveals DOTAGA promising for
Sudo H; Tsuji AB; Sugyo A; Harada Y; Nagayama S; Katagiri T; Nakamura Y; Higashi T
Cancer Sci; 2023 Dec; 114(12):4677-4690. PubMed ID: 37781962
[TBL] [Abstract][Full Text] [Related]
23. Preclinical assessment of IRDye800CW-labeled gastrin-releasing peptide receptor-targeting peptide for near infrared-II imaging of brain malignancies.
Zhang Y; Wang L; Zhang C; Zhang J; Yuan L; Jin S; Zhou W; Guan X; Kang P; Zhang C; Tian J; Chen X; Li D; Jia W
Bioeng Transl Med; 2023 Jul; 8(4):e10532. PubMed ID: 37476052
[TBL] [Abstract][Full Text] [Related]
24. Induction of multinucleated cells and apoptosis in the PC-3 prostate cancer cell line by low concentrations of polyethylene glycol 1000.
Fukuta K; Kohri K; Fukuda H; Watanabe M; Sugimura T; Nakagama H
Cancer Sci; 2008 May; 99(5):1055-62. PubMed ID: 18380794
[TBL] [Abstract][Full Text] [Related]
25. Formulation of patient dose of [
Amirdhanayagam J; Guleria M; Sharma R; Kumar N; Mukherjee A; Das T
J Labelled Comp Radiopharm; 2024 Apr; 67(4):131-144. PubMed ID: 38342496
[TBL] [Abstract][Full Text] [Related]
26. Formulation and clinical translation of [
Guleria M; Sharma R; Amirdhanayagam J; Sarma HD; Rangarajan V; Dash A; Das T
RSC Med Chem; 2021 Mar; 12(2):263-277. PubMed ID: 34046615
[TBL] [Abstract][Full Text] [Related]
27. A Proof-of-Concept Study on the Theranostic Potential of
Chen X; Tan F; Liang R; Liao J; Yang J; Lan T; Yang Y; Liu N; Li F
Chemistry; 2024 Feb; 30(9):e202303298. PubMed ID: 38050716
[TBL] [Abstract][Full Text] [Related]
28. Liquid Chromatography ICP-MS to Assess the Stability of
Wallimann RH; Hensinger H; Müller C; Schibli R; Kneuer R; Schindler P
Pharmaceutics; 2024 Feb; 16(3):. PubMed ID: 38543193
[TBL] [Abstract][Full Text] [Related]
29. Safety assessment, radioiodination and preclinical evaluation of antinuclear antibody as novel medication for prostate cancer in mouse xenograft model.
Nguyen TMC; Hoang LDC; Nguyen TKG; Nguyen TN; Nguyen QC; Nguyen TB; Dang HHQ; Bui VC; Pham TM; Nguyen TT
Sci Rep; 2023 Oct; 13(1):18753. PubMed ID: 37907691
[TBL] [Abstract][Full Text] [Related]
30. Radiolabelled
Cieslik PA; Klingler S; Nolff M; Holland JP
Chemistry; 2024 Mar; 30(14):e202303805. PubMed ID: 38064536
[TBL] [Abstract][Full Text] [Related]
31. Radioimmunotheranostic Pair Based on the Anti-HER2 Monoclonal Antibody: Influence of Chelating Agents and Radionuclides on Biological Properties.
Miranda ACC; Dos Santos SN; Fuscaldi LL; Balieiro LM; Bellini MH; Guimarães MICC; de Araújo EB
Pharmaceutics; 2021 Jun; 13(7):. PubMed ID: 34198999
[TBL] [Abstract][Full Text] [Related]
32. A Theranostic Cellulose Nanocrystal-Based Drug Delivery System with Enhanced Retention in Pulmonary Metastasis of Melanoma.
Imlimthan S; Khng YC; Keinänen O; Zhang W; Airaksinen AJ; Kostiainen MA; Zeglis BM; Santos HA; Sarparanta M
Small; 2021 May; 17(18):e2007705. PubMed ID: 33738957
[TBL] [Abstract][Full Text] [Related]
33. Current clinical application of lutetium‑177 in solid tumors (Review).
Niu T; Fan M; Lin B; Gao F; Tan B; Du X
Exp Ther Med; 2024 May; 27(5):225. PubMed ID: 38596660
[TBL] [Abstract][Full Text] [Related]
34. Radionuclide therapy using ABD-fused ADAPT scaffold protein: Proof of Principle.
Garousi J; von Witting E; Borin J; Vorobyeva A; Altai M; Vorontsova O; Konijnenberg MW; Oroujeni M; Orlova A; Tolmachev V; Hober S
Biomaterials; 2021 Jan; 266():120381. PubMed ID: 33120197
[TBL] [Abstract][Full Text] [Related]
35.
Wang L; Bratanovic IJ; Zhang Z; Kuo HT; Merkens H; Zeisler J; Zhang C; Tan R; Bénard F; Lin KS
Molecules; 2023 Feb; 28(4):. PubMed ID: 36838968
[TBL] [Abstract][Full Text] [Related]
36. Gastrin-releasing peptide receptor agonists and antagonists for molecular imaging of breast and prostate cancer: from pre-clinical studies to translational perspectives.
Gorica J; De Feo MS; Filippi L; Frantellizzi V; Schillaci O; De Vincentis G
Expert Rev Mol Diagn; 2022 Nov; 22(11):991-996. PubMed ID: 36369779
[TBL] [Abstract][Full Text] [Related]
37. Heterodimeric Radiotracer Targeting PSMA and GRPR for Imaging of Prostate Cancer-Optimization of the Affinity towards PSMA by Linker Modification in Murine Model.
Lundmark F; Abouzayed A; Mitran B; Rinne SS; Varasteh Z; Larhed M; Tolmachev V; Rosenström U; Orlova A
Pharmaceutics; 2020 Jul; 12(7):. PubMed ID: 32630176
[TBL] [Abstract][Full Text] [Related]
38. Bispecific GRPR-Antagonistic Anti-PSMA/GRPR Heterodimer for PET and SPECT Diagnostic Imaging of Prostate Cancer.
Mitran B; Varasteh Z; Abouzayed A; Rinne SS; Puuvuori E; De Rosa M; Larhed M; Tolmachev V; Orlova A; Rosenström U
Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31540122
[TBL] [Abstract][Full Text] [Related]
39. GRPR-Antagonists Carrying DOTAGA-Chelator via Positively Charged Linkers: Perspectives for Prostate Cancer Theranostics.
Obeid K; Kanellopoulos P; Abouzayed A; Mattsson A; Tolmachev V; Nock BA; Maina T; Orlova A
Pharmaceutics; 2024 Apr; 16(4):. PubMed ID: 38675174
[TBL] [Abstract][Full Text] [Related]
40. Preclinical evaluation of new GRPR-antagonists with improved metabolic stability for radiotheranostic use in oncology.
Kanellopoulos P; Mattsson A; Abouzayed A; Obeid K; Nock BA; Tolmachev V; Maina T; Orlova A
EJNMMI Radiopharm Chem; 2024 Feb; 9(1):13. PubMed ID: 38366299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
